Copyright
©The Author(s) 2022.
World J Gastroenterol. Jul 28, 2022; 28(28): 3535-3554
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3535
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3535
Figure 1 General structure and ligand-activated transcription of peroxisome proliferator-activated receptor-gamma.
A: Peroxisome proliferator-activated receptor (PPAR) structure includes four distinct structural domains A/B, C, D, and E/F; B: Ligand-activated transcription of PPARγ, which includes heterodimerization with nuclear receptor retinoid X receptor (RXR) and binding with peroxisome proliferator response elements located in the target genes through the DNA-binding domain (DBD). In the absence of ligand, PPAR is linked with the corepressor complex, whereas, in the presence of ligand, it is associated with the coactivator complex. LBD: Ligand-binding domain; PPRE: Peroxisome proliferator response element.
- Citation: Katoch S, Sharma V, Patial V. Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios. World J Gastroenterol 2022; 28(28): 3535-3554
- URL: https://www.wjgnet.com/1007-9327/full/v28/i28/3535.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i28.3535